Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
24.18
+1.62 (7.18%)
At close: Jul 30, 2026, 4:00 PM EDT
24.31
+0.13 (0.54%)
After-hours: Jul 30, 2026, 5:01 PM EDT
Adaptive Biotechnologies Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Adaptive Biotechnologies stock has a consensus rating of "Buy" and an average price target of $23.86. The average 1-year stock price forecast is 1.32% lower than the current stock price, while the lowest is $20 (-17.29%) and the highest is $28 (+15.80%).
Price Target: $23.86 (-1.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Adaptive Biotechnologies stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Craig-Hallum | Craig-Hallum | Buy Maintains $21 | Buy | Maintains | $21 | -13.15% | Jul 30, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $25 → $27 | Buy | Maintains | $25 → $27 | +11.66% | Jul 30, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $20 | Buy | Maintains | $20 | -17.29% | Jul 30, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -9.02% | Jul 30, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $22 → $25 | Buy | Reiterates | $22 → $25 | +3.39% | Jul 30, 2026 |
Financial Forecast
Revenue This Year
286.58M
from 276.98M
Increased by 3.47%
Revenue Next Year
352.21M
from 286.58M
Increased by 22.90%
EPS This Year
-0.45
from -0.39
EPS Next Year
-0.24
from -0.45
EPS and Forward PE are based on non-GAAP adjusted numbers.